Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Biological drugs have been a game-changer for people with severe asthma, helping them breathe easier and live more ...

Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet in Sweden shows that some immune cells with high inflammatory potential ...

After six months of starting Dupilumab, frequency of asthma symptoms decreased significantly with no asthma symptoms at rest, no nighttime awakenings, no prednisone use and no emergency room ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal document ...

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence.

Head-to-Head Trial Finds Winner for CRSwNP With Asthma Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to ...

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in ...

Mar. 12, 2025 — A lung function test used to help diagnose asthma works better in the morning, becoming less reliable throughout the day, researchers have found. Using real world data from 1,600 ...